You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Pfizer lifts sales forecast for coronavirus vaccine to $26 billion

This is reflecting new contracts with governments around the world trying to halt the pandemic through rapid vaccination.

Topics
Pfizer | Coronavirus Vaccine | Coronavirus Tests

Reuters 

Pfizer vaccine
Representational image

Inc on Tuesday forecast $26 billion in COVID-19 vaccine sales this year, a more than 70% jump from its last projection, reflecting new contracts with governments around the world trying to halt the pandemic through rapid vaccination.

The raised goal assumes 1.6 billion doses of vaccine, which is co-developed with BioNTech SE, will be delivered in the year, with the two-shot vaccine emerging as the best-selling product for the U.S. drugmaker in the first quarter.

It is expected to make up for more than one-third of Pfizer's full-year sales, with the company in supply talks with several countries for 2022 and beyond.

"Based on what we've seen, we believe that a durable demand for our COVID-19 vaccine - similar to that of the flu vaccines - is a likely outcome," Chief Executive Albert Bourla said in his prepared remarks.

Cost and gross profit from the vaccine are split 50-50 between and BioNTech. The two drugmakers had said they aim to produce up to 2.5 billion doses this year, of which 900 million doses have not been included in Pfizer's forecast.

If it sells that number of doses, the vaccine sales in 2021 could be at least 50% higher than the projected $26 billion.

The company has said it expects to profit from the vaccine, while some drugmakers including Johnson & Johnson have said their vaccine will be available on a not-for-profit basis until the end of the pandemic.

aims to manufacture at least 3 billion doses of the vaccine next year. It generated $3.5 billion in revenue in the first quarter and beat estimates of $3.28 billion, according to six analysts polled by Refinitiv.

Rival Moderna has forecast $18.4 billion in 2021 sales of its COVID-19 vaccine.

Pfizer said it was using the technology used in the COVID-19 shot known as messenger RNA to develop two flu vaccines that are expected to enter clinical studies in the third quarter.

Shares the company were up 1.4% in premarket trading.

 

(Reporting by Manas Mishra in Bengaluru and Michael Erman in Maplewood, N.J; Editing by Arun Koyyur)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, May 04 2021. 18:31 IST
RECOMMENDED FOR YOU